DAMLA YÜKSEL BALIM, ÖZLEM İZCİ AY, MUSTAFA ERTAN AY, ÜMİT KARAKAŞ, Ayşenur İNCİ KENAR, MEHMET EMİN ERDAL

Beyin kökenli nörotrofik faktör, nörotrofin-3 ve nörotrofin-4 gen ekspresyon değişimleri majör depresyonun patogenezinde etkili midir?

Amaç: Beyin kökenli nörotrofik faktör (BDNF), nörotrofin-3 (NT-3) ve nörotrofin-4 (NT-4); nöronal sağlıklı kalımın,farklılaşmanın, büyümenin ve nöronal plastisitenin düzenlenmesinde önemli rolleri olan nörotrofinlerdir. Nöropsiki-yatrik hastalıkların patofizyolojisi ile nörotrofik faktörlerin ifade düzeyleri arasındaki ilişki bilinmekle birlikte, majördepresyon (MD) patogenezi ve nörotrofinler arasındaki ilişki henüz tam olarak aydınlatılamamıştır. Bu çalışmada,kan hücrelerindeki BDNF, NT-3, NT-4 gen ekspresyonları ile MD arasındaki ilişkiyi araştırdık. Yöntem: Bu olgu-kontrol çalışmasında, DSM-5 ölçütlerine göre MD’li 51 hasta ve 75 sağlıklı kontrole ait kanlardan total RNA eldeedildi. Kantitatif Real-Time PCR yöntemi ile saptanan, MD ve kontrol gruplarındaki BDNF, NT-3, NT-4 genlerine aitekspresyon düzeyleri karşılaştırıldı. Bulgular: Çalışma sonucunda, MD hastalarının BDNF gen ekspresyon düzey-lerinin, kontrol grubuna göre anlamlı derecede yüksek olduğu; NT-3 ve NT-4 değerleri bakımından ise gruplar ara-sında istatistiksel olarak anlamlı bir farklılık olmadığı belirlendi. Aile öyküsü olan MD hastalarının BDNF, NT-3 veNT-4 ekspresyon düzeylerinde farklılık saptanmadı. Hasta grubu içinde cinsiyetler arasında ve antidepresan kulla-nım sürelerine göre, BDNF, NT-3 ve NT-4 ekspresyon düzeyleri bakımından istatistiksel olarak anlamlı bir farklılıkbulunmadı. Tartışma: MD hastalarının kan hücrelerindeki BDNF geni ekspresyon düzeyi değişiklikleri, sadeceMD'nin patogenezini anlamada değil, tedavinin izlenmesinde de, BDNF'nin perifer ile beyin arasındaki çift yönlühareketi ve serum BDNF düzeyini değiştirme etkisinden dolayı göz önünde bulundurulmalıdır. (Anadolu PsikiyatriDerg 2019; 20(6):581-588)

Are brain derived neurotrophic factor, neurotrophin-3 and neurotrophin-4 gene expression changes effective in the pathogenesis of major depression?

Objective: Brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4) are neuro- trophins and they are critical regulators of the survival, differentiation, growth and plasticity of neuronal networks. There is plenty of evidence suggesting the involvement of altered levels of expression of neurotrophic factors in the pathophysiology of neuropsychiatric disorders. However, the relationship between neurotrophins and majör depres- sion (MD) remains unclear. In this study, we assessed the relationship between the BDNF, NT-3, NT-4 gene ex- pression levels in blood cells and MD. Methods: In a case-control study, total RNA was obtained from blood cells, 51 MD patients (diagnosed according to the DSM-5 criteria) and 75 healthy controls. Detected with quantitative Real Time PCR, expression levels of BDNF, NT-3, NT-4 genes were compared between the groups. Results: In this study, BDNF expression levels of the patients with MD were significantly higher than the control group but no statistically significant difference between NT-3 and NT-4 expression levels. There was no differences in expression levels of BDNF, NT-3 and NT-4 genes in MD patients with family history. There was no statistically significant differ- ence in the BDNF, NTF-3 and NTF-4 expression levels among the sex groups for the patient group and no statis- tically significant difference between MD patients according to antidepressant usage time. Discussion: Not only in understanding the pathogenesis of MD but also in the follow-up of treatment, expression level changes of BDNF gene in blood cells of MD patients must be considered because of the bidirectional movement of BDNF between the periphery and the brain and effect of changing serum BDNF levels. (Anatolian Journal of Psychiatry 2019; 20(6):581-588)

PDF

___

Friedman ES, Anderson IM. Handbook of Depression. Second ed., USA: Springer Healthcare, 2011.
Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, et al. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2005; 2:590-611.
Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, De Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 2011; 9(90):1-16.
Fava M, Kendler KS. Major depressive disorder. Neuron 2000; 28:335-341.
Corfield EC, Yang Y, Martin NG, Nyholt DR. A continuum of genetic liability for minor and major depression. Transl Psychiatry 2017; 7:1-7.
Chao MV. Neurotrophins and their receptors: a conver- gence point for many signalling pathways. Nat Rev Neurosci 2003; 4:299-309.
Neto FL, Borges G, Torres-Sanchez S, Mico JA, Berro- coso E. Neurotrophins role in depression neurobiology: a review of basic and clinical evidence. Curr Neuro- pharmacol 2011; 9:530-552.
Castren E, Rantamaki T. The role of BDNF and its recep- tors in depression and antidepressant drug action: reacti- vation of developmental plasticity. Dev Neurobiol 2010; 70:289-297.
Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 2009; 43:247-254.
Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64:527-532.
Kishi T, Yoshimura R, Ikuta T, Iwata N. Brain-derived neurotrophic factor and major depressive disorder: evidence from meta-analyses. Front Psychiatry 2017; 8(308):1-5.
Molendijk ML, Bus BAA, Spinhoven P, Penninx BWJH, Kenis G, Prickaerts J, et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state- trait issues, clinical features and pharmacological treat- ment. Mol Psychiatry 2011; 16:1088-1095.
Ogłodek EA, Just MJ, Szromek AR, Araszkiewicz A. Melatonin and neurotrophins NT-3, BDNF, NGF in patients with varying levels of depression severity. Pharmacol Rep 2016; 68:945-951.
Gonul AS, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S. Effect of treatment on serum brain-derived neuro- trophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 2005; 255:381-386.
Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005; 26:115-123.
Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Zhang H, Pavuluri MN. Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:645-651.
Buturak SV, Basterzi AD, Yazici A, Yazici K, Acar ST. Comorbid disorders in outpatients with major depressive disorder and their sociodemographical aspects. J Mood Disorders 2011; 1:7-13.
Shimizu E, Hashimoto K, Watanabe H, Komatsu N, Oka-mura N, Koike K, et al. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistingu-ishable from controls. Neurosci Lett 2003; 351(2):111-114.
Huang TL, Lee CT, Liu YL. Serum brain-derived neuro-trophic factor levels in patients with major depression: effects of antidepressants. Psychiatric Res 2008; 42:521-525.
Colle R, Trabado S, David DJ, Brailly-Tabard S, Hardy P, et al. Plasma BDNF level in major depression: bio-marker of the Val66Met BDNF polymorphism and of the clinical course in met carrier patients. Neuropsycho-biology 2017; 75:39-45.
Aldoghachi AF, Tor YS, Redzun SZ, Bin Lokman KA, Abdul Razaq NA, et al. Screening of brain-derived neuro-trophic factor (BDNF) single nucleotide polymorphisms and plasma BDNF levels among Malaysian major de-pressive disorder patients. PLoS One 2019; 14(1):1-19.
Ziegenhorn AA, Schulte-Herbrüggen O, Danker-Hopfe H, Malbranc M, Hartung HD, Anders D, et al. Serum neurotrophins-a study on the time course and influencing factors in a large old age sample. Neurobiol Aging 2007; 28:1436-1445.
Paccinni A, Marazziti D, Catena M, Domenici L, Del Debbio A, Bianchi C, et al. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed pa-tients during 1 year of antidepressant treatments. J Affect Disord 2008; 105:279-283.
Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuro-plasticity in depression. Int J Neuropsychopharmacol 2008; 11:1169-1180.
Sheldrick SA, Ilieva PR, Michel TM. Brain-derived neuro-trophic factor (BDNF) and neurotrophin 3 (NT3) levels in post-mortem brain tissue from patients with depression compared to healthy individuals-a proof of concept study. Eur Psychiatry 2017; 46:65-71.
Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37:1553-1561.
Brunoni AR. Lower mRNA BDNF expression in lympho-cytes: endophenotype or epiphenomenon for major de-pression? (Letters to Editor) Prog Neuropsychophar-macol Biol Psychiatry 2010; 34:1160.
Cattaneo A, Bocchio-Chiavetto L, Zanardini R, Milanesi E, Placentino A, Gennarelli M. Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. Int J Neuropsychophar-macol 2010; 13:103-108.
Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ et al. Candidate genes expression profile associated with antidepressants response in the GENDEP Study: Differentiating between baseline ‘pre-dictors’ and longitudinal ‘targets’. Neuropsychopharma-cology 2013; 38:377-385.
Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, Umene W, et al. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1034-1037.
Hing B, Sathyaputri L, Potash JB. A comprehensive review of genetic and epigenetic mechanisms that regulate BDNF expression and function with relevance to major depressive disorder. Am J Med Genet 2018; 177:143-167.
Otsuki K, Uchida S, Watanuki T, Wakabayashi Y, Fujimoto M, Matsubara T, et al. Altered expression of neurotrophic factors in patients with major depression. J Psychiatr Res 2008; 42:1145-1153.